These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17373726)

  • 1. Malignant melanoma in early Parkinson's disease: the DATATOP trial.
    Constantinescu R; Romer M; Kieburtz K;
    Mov Disord; 2007 Apr; 22(5):720-2. PubMed ID: 17373726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with levodopa and risk for malignant melanoma.
    Olsen JH; Tangerud K; Wermuth L; Frederiksen K; Friis S
    Mov Disord; 2007 Jul; 22(9):1252-7. PubMed ID: 17534943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease, levodopa-use and the risk of melanoma.
    Vermeij JD; Winogrodzka A; Trip J; Weber WE
    Parkinsonism Relat Disord; 2009 Sep; 15(8):551-3. PubMed ID: 19501540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin cancer and Parkinson's disease.
    Ferreira JJ; Neutel D; Mestre T; Coelho M; Rosa MM; Rascol O; Sampaio C
    Mov Disord; 2010 Jan; 25(2):139-48. PubMed ID: 20063399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.
    Bertoni JM; Arlette JP; Fernandez HH; Fitzer-Attas C; Frei K; Hassan MN; Isaacson SH; Lew MF; Molho E; Ondo WG; Phillips TJ; Singer C; Sutton JP; Wolf JE;
    Arch Neurol; 2010 Mar; 67(3):347-52. PubMed ID: 20212233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease.
    Clarke CE; Moore AP
    Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619
    [No Abstract]   [Full Text] [Related]  

  • 9. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing clinical outcomes in residents with Parkinson's disease. Introduction.
    Libow LS
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):3. PubMed ID: 17948615
    [No Abstract]   [Full Text] [Related]  

  • 11. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population prevalence and incidence of Parkinson's disease in an Australian community.
    Mehta P; Kifley A; Wang JJ; Rochtchina E; Mitchell P; Sue CM
    Intern Med J; 2007 Dec; 37(12):812-4. PubMed ID: 17561942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.
    Toth C; Breithaupt K; Ge S; Duan Y; Terris JM; Thiessen A; Wiebe S; Zochodne DW; Suchowersky O
    Ann Neurol; 2010 Jul; 68(1):28-36. PubMed ID: 20582991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpreting the results of Parkinson's disease clinical trials: time for a change.
    Holford NH; Nutt JG
    Mov Disord; 2011 Mar; 26(4):569-77. PubMed ID: 21370266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restless legs syndrome in Parkinson's disease.
    Gómez-Esteban JC; Zarranz JJ; Tijero B; Velasco F; Barcena J; Rouco I; Lezcano E; Lachen MC; Jauregui A; Ugarte A
    Mov Disord; 2007 Oct; 22(13):1912-6. PubMed ID: 17579369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management approaches to dyskinesia vary from country to country.
    Woitalla D; Mueller T; Russ H; Hock K; Haeger DA
    Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pramipexole on the onset of levodopa-related dyskinesias.
    Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
    Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.